Literature DB >> 26563255

Prevention of infection-related cancers in the WHO Western Pacific Region.

Hai-Rim Shin1, Aesun Shin2, Hyeongtaek Woo2, Kimberley Fox3, Nick Walsh3, Ying-Ru Lo3, Eric Wiesen3, Cherian Varghese3.   

Abstract

A considerable number of infectious agents have been classified as human carcinogens Group 1 by the International Agency for Research on Cancer. Major infection-related cancers such as cancers of nasopharynx (53%), stomach (60%) and liver (63%) occur in the World Health Organization Western Pacific Region. Many infection-related cancers are preventable, particularly those associated with human papilloma virus, Helicobacter pylori, human immunodeficiency virus-I, hepatitis B virus and hepatitis C virus and liver flukes. Mongolia shows the highest prevalence of hepatitis B virus and hepatitis C virus, and China shows the highest prevalence of Helicobacter pylori. Chronic infection is attributable for 17-28% of overall cancer incidence or mortality in China, Japan and Korea. Through infant immunization for hepatitis B, 30 of 37 countries and areas in the Western Pacific Region have reached the 2012 milestone of chronic hepatitis B virus infection prevalence of <2% in 5-year-old children and countries and areas of the region are now striving toward reaching the regional goal of <1% by 2017. Human papilloma virus immunization program is implemented either by government funding or, in some low-income countries, by public and private sector organizations. Cervical cancer screening via visual inspection with acetic acid or Pap smear is available in many Western Pacific Region Member States. More efforts are needed to implement new World Health Organization guide to vaccinate 9- to 13-year-old girls with two doses of human papilloma virus vaccine, and use human papilloma virus tests to screen women to prevent and control cervical cancer including guaranteed monitoring and appropriate follow-up for abnormal results. © World Health Organization 2015. All rights reserved. The World Health Organization has granted the Publisher permission for the reproduction of this article.

Entities:  

Keywords:  cancer; infection; policy; prevalence

Mesh:

Substances:

Year:  2015        PMID: 26563255     DOI: 10.1093/jjco/hyv092

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  9 in total

1.  Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients.

Authors:  Won Young Tak; Baek-Yeol Ryoo; Ho Yeong Lim; Do-Young Kim; Takuji Okusaka; Masafumi Ikeda; Hisashi Hidaka; Jong-Eun Yeon; Eishiro Mizukoshi; Manabu Morimoto; Myung-Ah Lee; Kohichiroh Yasui; Yasunori Kawaguchi; Jeong Heo; Sojiro Morita; Tae-You Kim; Junji Furuse; Kazuhiro Katayama; Takeshi Aramaki; Rina Hara; Takuya Kimura; Osamu Nakamura; Masatoshi Kudo
Journal:  Invest New Drugs       Date:  2018-09-10       Impact factor: 3.850

2.  Seroprevalence of Hepatitis B Among HIV-infected Children and Adolescents Receiving Antiretroviral Therapy in the TREAT Asia Pediatric HIV Observational Database.

Authors:  Linda Aurpibul; Azar Kariminia; Ung Vibol; Moy Siew Fong; Oanh Ngoc Le; Rawiwan Hansudewechakul; Torsak Bunupuradah; Nia Kurniati; Kulkanya Chokephaibulkit; Nagalingeswaran Kumarasamy; Dewi Kumara Wati; Nik Khairulddin Nik Yusoff; Kamarul Azahar Mohd Razali; Revathy A Nallusamy; Annette H Sohn; Pagakrong Lumbiganon
Journal:  Pediatr Infect Dis J       Date:  2018-08       Impact factor: 2.129

3.  Modeling the Trend Changes of Liver Cancer Mortality in the 6 WHO Regions.

Authors:  Seyedeh Fatemeh Musavi Ezmareh; Kamran Mehrabani; Hadi Raeisi Shahraki
Journal:  Turk J Gastroenterol       Date:  2022-06       Impact factor: 1.555

4.  Helicobacter pylori-Negative Advanced Gastric Cancer Arising from the Gastric Mucosa without Inflammation, Atrophy, or Intestinal Metaplasia.

Authors:  Jiro Hayashi; Tomoki Yamatsuji; Mitsuhiko Suehiro; Ken Haruma; Ryo Katsumata; Hirofumi Kawamoto; Tomoari Kamada; Kazuhiro Yoshida; Masamichi Yoneda; Yasumasa Monobe; Yoshio Naomoto
Journal:  Case Rep Gastroenterol       Date:  2022-06-07

5.  Subtype-specific epidemiology of lymphoid malignancies in Taiwan compared to Japan and the United States, 2002-2012.

Authors:  Bor-Sheng Ko; Li-Ju Chen; Huai-Hsuan Huang; Yao-Chun Wen; Chi-Yin Liao; Ho-Min Chen; Fei-Yuan Hsiao
Journal:  Cancer Med       Date:  2018-10-09       Impact factor: 4.452

6.  The burden of primary liver cancer caused by specific etiologies from 1990 to 2019 at the global, regional, and national levels.

Authors:  Jianqing Yang; Guangdong Pan; Linjing Guan; Zhipeng Liu; Yongrong Wu; Zhen Liu; Wuchang Lu; Shuai Li; Honglai Xu; Guoqing Ouyang
Journal:  Cancer Med       Date:  2022-01-06       Impact factor: 4.452

7.  Frequencies of Porphyromonas gingivalis Detection in Oral-Digestive Tract Tumors.

Authors:  Jinyu Kong; Xiang Yuan; Jian Wang; Yiwen Liu; Wei Sun; Bianli Gu; Zijun Lan; Shegan Gao
Journal:  Pathol Oncol Res       Date:  2021-04-01       Impact factor: 3.201

8.  Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries.

Authors:  S M Garland; P Pitisuttithum; H Y S Ngan; C-H Cho; C-Y Lee; C-A Chen; Y C Yang; T-Y Chu; N-F Twu; R Samakoses; Y Takeuchi; T H Cheung; S C Kim; L-M Huang; B-G Kim; Y-T Kim; K-H Kim; Y-S Song; S Lalwani; J-H Kang; M Sakamoto; H-S Ryu; N Bhatla; H Yoshikawa; M C Ellison; S R Han; E Moeller; S Murata; M Ritter; M Sawata; C Shields; A Walia; G Perez; A Luxembourg
Journal:  J Infect Dis       Date:  2018-06-05       Impact factor: 5.226

9.  Association between the interferon-γ +874T/A polymorphism and susceptibility to hepatitis B virus infection: a meta-analysis.

Authors:  Liang Li
Journal:  J Int Med Res       Date:  2020-08       Impact factor: 1.671

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.